Kelvin Chiu

CEO of ALiA BioTech - Leadership Excellence in Biotechnology

Profile

Kelvin has over 20 years of various academic and business experiences in biomedical industry.

Kelvin has extensive experience in advanced biotechnology & operational strategy and has involved in multiple international M&A projects and global operations. He has extensive experience in pre-clinical project management and transition from prototype commercialization through product launch.

Mr. Chiu received his bachelor’s degree in biochemistry from UCLA, M.Phil.’s degree in molecular biology from the University of Hong Kong and MBA degree from UCLA Anderson School of Management, USA.

Kelvin worked at internationally leading organisations such as Children’s Hospital Los Angeles, Life Technologies.

FIRM PROFILE

ALiA BioTech is a group of companies that deliver accurate and actionable diagnostic information through our Point-Of-Care Testing (POCT) platform and BioChip, for faster clinical decisions and better economic outcomes for professional and front-line workers.

ALiA BioTech group is formed with our sole purpose of streamlining the way we response to diseases and driving innovations to shape the future of disease diagnostics. ALiA BioTech group has formed a diverse team in Hong Kong, China, France & USA, which is originated from a strong vision for transforming the diagnostic landscape with faster response to disease management.

Our Vision & Value
Since our establishment in December 2012, we intend to become a driving force of disease diagnostics and revolutionize healthcare solutions into the future, which is originated from a strong vision for transforming the diagnostic landscape with faster response to disease management.

In order to accomplish our vision, we have developed ALiA, an end-to-end Point-of-Care Testing (POCT) platform with digital healthcare management solutions for combating time-critical and life-threatening diseases and outbreaks.

ALiA Platform
ALiA Point-Of-Care Testing (POCT) platform is an end-to-end solution that delivers multiple results with a minimal drop of sample in 15 minutes in a Point-Of-Care (POC) setting.

ALiA is a portable and highly integrated microfluidic BioChip platform for time critical and life threatening disease diagnostics and fast-track triage at the medical front-line, with a whole series of BioChip applications for infectious diseases diagnostics and healthcare management.
ALiA is a miniaturized solution that consists of a microfluidic-microarray BioChip, an optical unit, an integrated control unit and a power supply system, which can run the BioChip without any fluidic interfaces to the instrument.

The platform includes a set of fluorescent immunoassay (FIA) analyzer and multifavious one-time use BioChip. The BioChip is based on a user-friendly, self-contained microfluidic Lab-On-Chip (LOC) with a protein-based microarray. The FIA analyzer is a fully automated device built with an intelligent optical sensing system. It is designed for medical professionals and less equipped workers at front lines to make faster clinical decisions and patient triage.

BioChip
Our BioChip is developed to tackle difficulties in distinguishing diseases with very similar symptoms and aid front-line professionals with making patient management decisions. This is achieved by targeting multiple diseases through a microarray.

With our microarray embedded BioChip, front-line workers can receive multiple disease diagnostic results right next to patients and immediately prescribe accurate medication and necessary treatment.

With our multiplex BioChip, we provide diagnostics for:

• 5-in-1 respiratory diseases including SARS-CoV-2, RSV, Streptococcus, Influenza A and Influenza B
• Tropical Diseases
• Sexually Transmitted Diseases
• Sepsis
• Gastrointestinal Infections

Benefiting from our well-established Lab-On-Chip (LOC) platform (including the POC device and the Lab-On-Chip BioChip), the multiplexing microarray development for various test panels (e.g. 5-in-1 respiratory virus panel) is scalable with a short period of 6-9 months for new application adaption.